pantoprazole has been researched along with Esophagitis in 30 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gastro-oesophageal reflux disease (Los Angeles grades A-D) patients were randomised to 4 weeks of treatment with pantoprazole-Mg (n = 290) or esomeprazole (n = 288), both 40 mg once daily, in this multicentre (14 Brazilian sites in 9 cities), double-blind study, with an additional 4 weeks' treatment in nonresponding patients." | 9.19 | Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. ( Moraes-Filho, JP; Pedroso, M; Quigley, EM, 2014) |
| "Patients with gastro-oesophageal reflux disease who are unable to swallow the tablet may safely be prescribed the pantoprazole sodium granules." | 9.12 | Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. ( Comer, GM; Ducker, S; Hogan, D; Pratha, V; Rath, N; Riff, D; Schwartz, H; Soffer, E; Wang, W, 2007) |
| "Once-daily pantoprazole therapy prevented relapse of healed erosive oesophagitis more effectively than ranitidine and with fewer heartburn days." | 9.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| " pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study." | 9.11 | A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. ( Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis." | 9.10 | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. ( Bochenek, WJ; Metz, DC, 2003) |
| "The proton pump inhibitor pantoprazole decreases both acid and bile reflux." | 9.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "This study was embarked upon to evaluate the effects of pantoprazole and palonosetron on experimental esophagitis in albino wistar rats." | 7.83 | Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats. ( Gautam, S; Kaithwas, G; Kumar, A; Rawat, JK; Saraf, SA; Singh, M, 2016) |
| " She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension." | 7.81 | [Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015) |
| "Treatment with lycopene evidenced sententious physiological protection when scrutinized for pH, acidity (total and free), volume of gastric juices and esophagitis index." | 7.81 | Effect of lycopene against gastroesophageal reflux disease in experimental animals. ( Gautam, S; Giri, AK; Kaithwas, G; Rawat, JK; Singh, M, 2015) |
| "The BGERDS was shown to be valid and reliable." | 5.33 | Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. ( Ciconelli, R; de Souza Cury, M; Ferrari, AP; Ferraz, MB; Moraes-Filho, JP, 2006) |
| "Gastro-oesophageal reflux disease (Los Angeles grades A-D) patients were randomised to 4 weeks of treatment with pantoprazole-Mg (n = 290) or esomeprazole (n = 288), both 40 mg once daily, in this multicentre (14 Brazilian sites in 9 cities), double-blind study, with an additional 4 weeks' treatment in nonresponding patients." | 5.19 | Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. ( Moraes-Filho, JP; Pedroso, M; Quigley, EM, 2014) |
| "To investigate the influence of irritable bowel syndrome (IBS)-like symptoms on treatment outcomes with pantoprazole in gastroesophageal reflux disease (GERD) in a real life setting." | 5.15 | Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. ( Doerfler, H; Heading, RC; Mönnikes, H; Schmitt, H, 2011) |
| "Patients with gastro-oesophageal reflux disease who are unable to swallow the tablet may safely be prescribed the pantoprazole sodium granules." | 5.12 | Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. ( Comer, GM; Ducker, S; Hogan, D; Pratha, V; Rath, N; Riff, D; Schwartz, H; Soffer, E; Wang, W, 2007) |
| "A total of 320 patients over 65 years with endoscopically diagnosed esophagitis were randomly assigned to one of the following treatments for 8 wk: (1) omeprazole 20 mg/d; (2) lansoprazole 30 mg/d; (3) pantoprazole 40 mg/d, or (4) rabeprazole 20 mg/d." | 5.12 | Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. ( Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D, 2007) |
| "Once-daily pantoprazole therapy prevented relapse of healed erosive oesophagitis more effectively than ranitidine and with fewer heartburn days." | 5.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| " pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study." | 5.11 | A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. ( Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis." | 5.10 | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. ( Bochenek, WJ; Metz, DC, 2003) |
| "The proton pump inhibitor pantoprazole decreases both acid and bile reflux." | 5.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "This study was embarked upon to evaluate the effects of pantoprazole and palonosetron on experimental esophagitis in albino wistar rats." | 3.83 | Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats. ( Gautam, S; Kaithwas, G; Kumar, A; Rawat, JK; Saraf, SA; Singh, M, 2016) |
| " She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension." | 3.81 | [Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015) |
| "Treatment with lycopene evidenced sententious physiological protection when scrutinized for pH, acidity (total and free), volume of gastric juices and esophagitis index." | 3.81 | Effect of lycopene against gastroesophageal reflux disease in experimental animals. ( Gautam, S; Giri, AK; Kaithwas, G; Rawat, JK; Singh, M, 2015) |
| "Pantoprazole is a gastric hydrogen-potassium adenosine triphosphatase (H+/K(+)-ATPase) inhibitor." | 2.41 | Pantoprazole. ( Poole, P, 2001) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "Combination therapy for GERD is preferred in patients with EE." | 1.72 | [Esophagoprotective therapy in patients with erosive esophagitis]. ( Bakulina, NV; Ilchishina, TA; Tikhonov, SV; Topalova, YG; Vasiliev, RV, 2022) |
| " PPI treatment continues to be the optimal management strategy for most patients with gastroesophageal reflux disease and is indicated for chronic use as ulcer prophylaxis in nonsteroidal anti-inflammatory drug takers at high risk for bleeding." | 1.36 | Editorial: just how "difficult" is it to withdraw PPI treatment? ( Howden, CW; Kahrilas, PJ, 2010) |
| "Validation of GERDyzer indicated high internal consistency (Cronbach's alpha = 0." | 1.35 | International validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux disease. ( Chassany, O; Devault, KR; Doerfler, H; Gebauer, U; Holtmann, G; Malagelada, JR; Schmitt, H, 2009) |
| " Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration." | 1.35 | Long-term proton pump inhibitor use in children: a retrospective review of safety. ( Boyer, K; Tolia, V, 2008) |
| "The BGERDS was shown to be valid and reliable." | 1.33 | Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. ( Ciconelli, R; de Souza Cury, M; Ferrari, AP; Ferraz, MB; Moraes-Filho, JP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 16 (53.33) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vaezi, MF | 1 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 2 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 1 |
| Bakulina, NV | 1 |
| Tikhonov, SV | 1 |
| Topalova, YG | 1 |
| Ilchishina, TA | 1 |
| Vasiliev, RV | 1 |
| Cho, JH | 1 |
| Yoon, H | 1 |
| Shin, CM | 1 |
| Park, YS | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Arya, E | 1 |
| Saha, S | 1 |
| Saraf, SA | 2 |
| Kaithwas, G | 3 |
| De, S | 1 |
| Williams, GS | 1 |
| Moraes-Filho, JP | 2 |
| Pedroso, M | 1 |
| Quigley, EM | 1 |
| Kumar, A | 1 |
| Gautam, S | 2 |
| Rawat, JK | 2 |
| Singh, M | 2 |
| Scheppach, W | 1 |
| Meesmann, M | 1 |
| Giri, AK | 1 |
| Holtmann, G | 1 |
| Chassany, O | 1 |
| Devault, KR | 1 |
| Schmitt, H | 2 |
| Gebauer, U | 1 |
| Doerfler, H | 2 |
| Malagelada, JR | 1 |
| Sharova, EP | 1 |
| Yaghoobi, M | 1 |
| Padol, S | 1 |
| Yuan, Y | 1 |
| Hunt, RH | 1 |
| Kahrilas, PJ | 1 |
| Bjornsson, E | 1 |
| Mönnikes, H | 1 |
| Heading, RC | 1 |
| Dabney-Smith, K | 1 |
| Nam, J | 1 |
| Ghazale, A | 1 |
| Cai, Q | 1 |
| Metz, DC | 2 |
| Bochenek, WJ | 2 |
| Karlstadt, RG | 1 |
| Walker, K | 1 |
| Richter, JE | 1 |
| Fraga, P | 1 |
| Mack, M | 1 |
| Sabesin, SM | 1 |
| Bochenek, W | 1 |
| Mack, ME | 1 |
| Fraga, PD | 1 |
| Katz, PO | 1 |
| Labenz, J | 1 |
| Armstrong, D | 1 |
| Lauritsen, K | 1 |
| Katelaris, P | 1 |
| Schmidt, S | 1 |
| Schütze, K | 1 |
| Wallner, G | 1 |
| Juergens, H | 1 |
| Preiksaitis, H | 1 |
| Keeling, N | 1 |
| Nauclér, E | 1 |
| Eklund, S | 1 |
| de Souza Cury, M | 1 |
| Ferrari, AP | 1 |
| Ciconelli, R | 1 |
| Ferraz, MB | 1 |
| Hogan, D | 1 |
| Pratha, V | 1 |
| Riff, D | 1 |
| Ducker, S | 1 |
| Schwartz, H | 1 |
| Soffer, E | 1 |
| Wang, W | 1 |
| Rath, N | 1 |
| Comer, GM | 1 |
| Tolia, V | 1 |
| Boyer, K | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Scarcelli, C | 1 |
| D'Ambrosio, LP | 1 |
| Paris, F | 1 |
| Annese, V | 1 |
| Seripa, D | 1 |
| Andriulli, A | 1 |
| Di Mario, F | 1 |
| Dam, C | 1 |
| Bygum, A | 1 |
| Brunner, G | 1 |
| Harke, U | 1 |
| Poole, P | 1 |
| Netzer, P | 1 |
| Gut, A | 1 |
| Brundler, R | 1 |
| Gaia, C | 1 |
| Halter, F | 1 |
| Inauen, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, P[NCT01132638] | Phase 3 | 713 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pantoprazole and Esophagitis
| Article | Year |
|---|---|
Esophagitis dissecans superficialis: a case report and literature review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Anti-Ulcer Agents; Deglutition Disorders | 2013 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazo | 2010 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph | 2004 |
Pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2001 |
10 trials available for pantoprazole and Esophagitis
| Article | Year |
|---|---|
Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study.
Topics: Adult; Aged; Artemisia; Double-Blind Method; Drug Therapy, Combination; Endoscopy, Digestive System; | 2020 |
Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 2014 |
Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Comorbidity; Esophagitis; Female; | 2011 |
Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aluminum Hydroxide; Anti-Ulcer Agents; Benzimi | 2003 |
Prevention of erosive oesophagitis relapse with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Eso | 2004 |
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2005 |
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Analysis of | 2007 |
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gast | 2007 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
15 other studies available for pantoprazole and Esophagitis
| Article | Year |
|---|---|
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
[Esophagoprotective therapy in patients with erosive esophagitis].
Topics: Antacids; Chondroitin Sulfates; Esophagitis; Gastroesophageal Reflux; Humans; Hyaluronic Acid; Panto | 2022 |
Effect of Perilla frutescens fixed oil on experimental esophagitis in albino Wistar rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; alpha-Linolenic Acid; Animals; Catalase; Esophagitis; Male; | 2013 |
Effect of palonosetron (5HT-3 antagonist) and pantoprazole (proton pump inhibitor) against surgical esophagitis induced by forestomach and pylorus ligation in albino rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Arachidonate 15-Lipoxygenase; Biomarkers; Cyclooxy | 2016 |
[Exfoliative esophagitis while taking dabigatran].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antithrombins; Atrial Fibrillation | 2015 |
Effect of lycopene against gastroesophageal reflux disease in experimental animals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antioxidants; Carotenoids; Catalase; Esophagitis; | 2015 |
International validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esophagitis; Female; Gastro | 2009 |
[Preparation sanpraz (pantoprazole): experience of application in treatment of gastroesophageal reflux disease and other acid related diseases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Gastric Aci | 2008 |
Editorial: just how "difficult" is it to withdraw PPI treatment?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophagitis; Gastric Acid; Gastroesophageal Refl | 2010 |
It is difficult to discontinue PPI treatment in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Esophagitis; Gastric A | 2011 |
Severe esophagitis healed in less than a week with intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Fema | 2003 |
Update on prescribing information for pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Digoxin; | 2003 |
Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Brazil; Endosco | 2006 |
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Hum | 2008 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans | 2008 |